Bronchopulmonary Dysplasia - A Pipeline Analysis Report

Overview of the drug development pipeline for bronchopulmonary dysplasia

Bronchopulmonary dysplasia is a chronic respiratory infection that occurs in newborn, premature, or low birth weight babies, born with intense respiratory distress syndrome. This condition is characterized by rapid and shallow breathing. Infants suffering from this condition experience chronic cough, staining of the skin, tachypnea, frequent desaturations, and flaring of nostrils while inhaling. In addition, these infants are kept in a breathing machine (mechanical ventilation) for a long time. Technavio’s market research analysts have predicted that with the introduction of oxygen therapy and mechanical ventilation as some of the most promising approaches to treat bronchopulmonary dysplasia, and this factor will aid in bronchopulmonary dysplasia market growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical development stage. For instance, sponsors such as Airway Therapeutics developed AT-100 and Meridigen Biotechnology developed UMC119-01, which are under the pre-clinical stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the phase III and phase II/III development stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the phase II stage.

Bronchopulmonary dysplasia: Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of bronchopulmonary dysplasia. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• Shire
• MEDIPOST
• Therabron

Therapeutic assessment of the drug development pipeline for bronchopulmonary dysplasia by route of administration

• Intratracheal
• Intravenous
• Inhaled
• Oral

According to bronchopulmonary dysplasia market analysis, the intratracheal route of administration (ROA) involves the administration of drug substances into the trachea. It has been observed that the majority of total therapeutics are being developed for intratracheal administration.

Therapeutic assessment of the drug development pipeline for bronchopulmonary dysplasia by therapeutic modalities

• Small molecule
• Biomolecule

Based on the bronchopulmonary dysplasia market forecast, the majority of molecules that are currently in the drug development pipeline for bronchopulmonary dysplasia are being developed as biomolecules. Biomolecules include macromolecules or polyanions such as proteins, carbohydrates, starches, lipids, and nucleic acids and small molecules such as auxiliary metabolites, natural products, and essential metabolites.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for bronchopulmonary dysplasia?
• What are the companies that are currently involved in the development of drug development molecules for bronchopulmonary dysplasia?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.